• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Senseonics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update

    1/2/26 7:00:35 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care
    Get the next $SENS alert in real time by email
    false 0001616543 0001616543 2025-12-31 2025-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): December 31, 2025

     

    SENSEONICS HOLDINGS, INC.
    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware   001-37717   47-1210911
    (State or Other
    Jurisdiction of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    20451 Seneca Meadows Parkway
    Germantown, MD 20876-7005
    (Address of Principal Executive Office) (Zip Code)

     

    Registrant's telephone number, including area code: (301) 515-7260

     

    Not Applicable

    Former name or former address, if changed since last report

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock SENS Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    Master Asset Purchase Agreement

     

    On December 31, 2025 (the “Execution Date”), Senseonics Holdings, Inc. (the “Company”), Senseonics, Incorporated, a wholly-owned subsidiary of the Company (“Senseonics Inc.” and together with the Company, the “Purchaser Parties”) and Ascensia Diabetes Care Holdings AG (the “Seller”) entered into a master asset purchase agreement (the “Master Asset Purchase Agreement”), pursuant to which, among other things, the Purchaser Parties agreed to acquire Seller’s and as applicable, Seller’s affiliates’, right, title and interest in and to certain assets related Seller’s marketing, selling and distribution of the Eversense® product in the United States (such assets, the “U.S. Purchased Assets”). Pursuant to the terms of the Master Asset Purchase Agreement, the Purchaser Parties agreed to assume certain liabilities and obligations associated with the U.S. Purchased Assets (the “U.S. Assumed Liabilities” and together with the U.S. Purchased Assets, the “U.S. Asset Purchase”), including, but not limited to, certain liabilities under the contracts transferred to the Purchaser Parties under the Master Asset Purchase Agreement, liabilities arising out of the use or ownership of the transferred assets after the closing, and liabilities and obligations arising from certain employees whose employment is transferred to Senseonics Inc. pursuant to new employment letter agreements with Senseonics Inc. The U.S. Asset Purchase closed on January 1, 2026 (the “U.S. Closing”).

     

    Subject to the terms and conditions of the Master Asset Purchase Agreement, as well as the negotiation and execution of local asset purchase agreements (the “Local Purchase Agreements”) by the Seller and the Purchaser Parties, the Purchaser Parties and/or their affiliates intend to acquire certain additional assets related to Seller’s commercial Eversense CGM activities in Italy, Germany, Spain and Sweden (such assets, the “European Purchased Assets”) and in connection therewith will agree to assume certain liabilities and obligations associated with the European Purchased Assets (the “European Assumed Liabilities” and together with the European Purchased Assets, the “European Asset Purchases”). The European Asset Purchases remain subject to further negotiation and the execution of Local Purchase Agreements to be entered into by Seller and/or its affiliates and the Purchaser Parties and/or their respective affiliates, which the parties will use commercially reasonable efforts to conclude in January 2026. The closing of each of the European Asset Purchases will be subject to the terms and conditions set forth in the Master Asset Purchase Agreement and the Local Purchase Agreements to be entered into between the parties, and would be expected to close on or before June 30, 2026 (the “European Closings” and, together with the U.S. Closing, the “Closings”).

     

    Pursuant to the Master Asset Purchase Agreement, in conjunction with the U.S. Closing, the Purchaser Parties will pay the Seller an aggregate cash payment of approximately $1.1 million, which primarily represents the Reference Balance Sheet Value (as defined in the Master Asset Purchase Agreement) of the acquired U.S. Purchased Assets (consisting of items such as inventory, pre-paid software licenses, and the asset value of certain car leases), subject to certain post-closing purchase price adjustments as set forth in the Master Asset Purchase Agreement. With respect to the European Closings, it is expected that the Purchaser Parties will make a cash payment under each Local Purchase Agreement of the respective Reference Balance Sheet Value based on the acquired European Purchased Assets, which are primarily expected to consist of inventory.

     

    The Master Asset Purchase Agreement contains customary representations, warranties, conditions and covenants, including covenants (i) concerning the conduct of business by the Seller prior to the Closings and (ii) prohibiting the Seller and its representatives from soliciting or encouraging any other acquisition inquiry, proposal or offer and indemnification by each of the parties. In addition, the Seller and the Purchaser Parties have agreed to reasonably cooperate with each other and use (and shall cause their respective affiliates to use) their respective reasonable best efforts to take or cause to be taken all actions, and to do or cause to be done all things, reasonably necessary to consummate the transactions contemplated by the Master Asset Purchase Agreement, including, after Local Purchase Agreements are executed, the European Asset Purchases.

     

    Each party’s obligation to consummate the transactions contemplated by the Master Asset Purchase Agreement is conditioned upon certain closing conditions, including the accuracy of the other party’s representations and warranties as of the Closings, subject, in certain instances, to certain materiality and other thresholds, the performance by the other party of its obligations and covenants under the Master Asset Purchase Agreement in all material respects, the absence of material adverse events and the absence of any injunction or other legal prohibitions preventing consummation of the transactions contemplated by the Master Asset Purchase Agreement and such conditions shall apply to the European Closings. In addition, the European Closings are expected to be subject to closing conditions required by the Local Purchase Agreements, which are anticipated to include without limitation certain regulatory clearances, consents or non-objection with respect to the transfer of tender contracts, and the conclusion required labor and employment processes.

     

     

     

     

    Amended and Restated Collaboration and Commercialization Agreement

     

    In connection with entering into the Master Asset Purchase Agreement, Senseonics Inc. and the Seller entered into an Amended and Restated Collaboration and Commercialization Agreement (the “A&R Collaboration Agreement”) on the Execution Date, which amended and restated that certain Collaboration and Commercialization Agreement, dated August 9, 2020, between Senseonics Inc. and the Seller, as amended to date (the “Existing Agreement”). Pursuant to the A&R Collaboration Agreement, the Seller’s right to market Eversense products in the U.S. have been terminated and the rights in the European Territories have been made non-exclusive. In order to support the orderly transition of the business pending the European Closings and the transfer of tender contracts in certain European Territories the Seller has agreed to continue to sell and market the Eversense product in the European Territories in a manner consistent with the A&R Collaboration Agreement and agreed upon performance standards. These rights and obligations apply from January 1, 2026 until the later of January 1, 2027, the transfer of all tender contracts, or the wind down of certain other commercial activities. Following the U.S. Closing, the Seller has no further rights to revenues from the sale of Eversense products in the U.S. Pursuant to the A&R Collaboration Agreement, effective January 1, 2026, Senseonics, Inc. will be entitled to 100% of the revenues derived from the sale of Eversense products in the European Territories. Senseonics will pay for certain transition services, and certain other costs, to maintain and achieve the orderly transition of the commercial operations in the European Territories, as outlined under “Transition Services Agreement” below.

     

    In conjunction with the execution of the Master Asset Purchase Agreement, and the A&R Collaboration Agreement (collectively, the “Agreements”), each party has agreed to certain indemnification obligations and limitations, as well a mutual release of the other party’s direct obligations relating to the transactions contemplated by the Agreements, subject to certain exceptions.

     

    In connection with the execution of the Master Asset Purchase Agreement and Koichiro Sato’s resignation from the board of directors of the Company, as described in Item 5.02 of this report, PHC Holdings Corporation, the parent company of the Seller, has advised the Company that it will not effect any transactions in the securities of the Company during the twelve month period ending December 31, 2026.

     

    The foregoing descriptions of the Agreements are not complete and are qualified in its entirety by reference to the Master Asset Purchase Agreement and the A&R Collaboration Agreement, each of which will be filed as exhibits to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

     

    Transition Services Agreement

     

    In connection with entering into the Local Purchase Agreements and the European Asset Purchases, Senseonics Inc. and the Seller intend to enter into a transition services agreement with the Seller (the “Transition Services Agreement”), pursuant to which the Seller would provide Senseonics Inc. with certain transition services in the European Territories to maintain the value of the business, support the preparation and execution of the transfer of operations to new Senseonics legal entities in the European Territories, and provide for the continuity of commercial operations relating to the Eversense product in the European Territories. Senseonics expects that it will pay certain costs and service fees under this arrangement. Services expected to be provided include support in the areas of logistics and ordering, payment and collections, claims processing, with respect to performance under tender contracts in the European Territories, IT and systems migration, business employee support, finance and operations support, regulatory compliance, and other agreed services, in each case, expected to be provided until dates up to June 30, 2026, subject to extension in certain cases.

     

     

     

     

    Forward-Looking Statements

     

    This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which include, but are not limited to, statements regarding or implying the Company’s expectations and intentions regarding the effects of the Agreements and the transactions contemplated thereunder, the completion of the European Closings, the timing, progress and results of the transfer of commercial operations relating to the Eversense product from the Seller to the Purchaser Parties and other statements that do not relate solely to historical or current facts. In some cases, these statements include words like: “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances, including but not limited to risks and uncertainties related to: the negotiation, finalization and execution of the Local Purchase Agreements, the ability of the parties to receive the required consents to consummate the European Asset Purchases in one or more European Territories, satisfaction of closing conditions precedent to the consummation of the European Asset Purchases, potential delays in consummating the Closings, the execution costs to the Company of the transactions contemplated by the Agreements and the impact of these costs and other liabilities on the Company’s cash, property and other assets, and uncertainties in connection with the transition of the commercial organization from the Seller to the Company, including potential disruptions in relationships with employees, patients, prescribers, distributors or regulatory authorities. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” and elsewhere in the Company’s most recent filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, and any subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at www.sec.gov.

     

    The forward-looking statements included in this report are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On the Execution Date, in connection with the transactions described in Item 1.01 of this report, Koichiro Sato, Senior Executive Vice President, Representative Director and Chief Operating Officer of PHC Holdings Corporation, the parent company of the Seller, notified the board of directors (the “Board”) of the Company of his resignation from the Board effective immediately. Mr. Sato’s resignation is not due to any disagreements with the Company, management or Board on any matter relating to the Company’s operations, policies, or practices.

     

    Mr. Sato served as a director of the Company pursuant to the designation by PHC Holdings Corporation pursuant to its rights under the Investor Rights Agreement dated as of August 9, 2020 (the “Rights Agreement”). As of the date hereof, PHC Holdings retains the right to designate one individual to serve as a director of the Company. Concurrently with the execution of the Master Purchase Agreement, PHC Holdings Corporation advised the Company that it does not presently intend to exercise its right under the Rights Agreement to designate any individual to serve on the Board.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: January 2, 2026 SENSEONICS HOLDINGS, INC.
     
      By: /s/ Rick Sullivan
      Name: Rick Sullivan
      Title: Chief Financial Officer

     

     

     

    Get the next $SENS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SENS

    DatePrice TargetRatingAnalyst
    10/21/2025$9.00Hold
    Stifel
    8/27/2025$1.50Overweight
    Barclays
    7/15/2025$1.25Buy
    TD Cowen
    6/2/2025$1.10Buy
    H.C. Wainwright
    4/10/2025$2.00Outperform
    Mizuho
    7/19/2023$0.50Underperform
    Jefferies
    8/19/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SENS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fiorentino Edward was granted 2,398 shares, increasing direct ownership by 3% to 71,363 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    1/5/26 5:45:06 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Director Roeder Douglas A was granted 2,504 shares, increasing direct ownership by 3% to 102,231 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    1/5/26 5:45:10 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Director Prince Douglas S was granted 1,379 shares, increasing direct ownership by 2% to 56,743 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    1/5/26 5:45:11 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel resumed coverage on Senseonics with a new price target

    Stifel resumed coverage of Senseonics with a rating of Hold and set a new price target of $9.00

    10/21/25 7:22:14 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Barclays initiated coverage on Senseonics with a new price target

    Barclays initiated coverage of Senseonics with a rating of Overweight and set a new price target of $1.50

    8/27/25 8:26:33 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    TD Cowen initiated coverage on Senseonics with a new price target

    TD Cowen initiated coverage of Senseonics with a rating of Buy and set a new price target of $1.25

    7/15/25 8:44:36 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Senseonics Announces First Commercial Patients Using Eversense 365 Continuous Glucose Monitor (CGM) with twiist™ Automated Insulin Delivery (AID) System

    GERMANTOWN, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable CGM systems for people with diabetes with Sequel MedTech, LLC, a company developing state-of-the-art insulin delivery technologies, have launched the integration of their products with the first patients having received a Sequel twiist AID system paired with the Eversense 365 CGM. The commercial launch of the integrated products provides people with type 1 diabetes a new level of flexibility and personalization in their diabetes management. Pairing twiist™ with Senseonics' Eversens

    1/8/26 4:01:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Senseonics Holdings, Inc. to Participate in the Stifel 2025 Healthcare Conference

    GERMANTOWN, Md., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Stifel 2025 Healthcare Conference, being held in New York, NY. 2025 Stifel Healthcare Conference Format: Fireside chat and one-on-one meetingsDate: Wednesday, November 12, 2025Time: 4:40 pm ETWebcast: Click here Interested parties may access a live and recorded webcast of the presentation on the "Investor Relations" section of the company's website at www.senseonics.com. About Se

    11/10/25 8:05:00 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    SEC Filings

    View All

    $SENS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Senseonics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update

    8-K - Senseonics Holdings, Inc. (0001616543) (Filer)

    1/2/26 7:00:35 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    SEC Form CERT filed by Senseonics Holdings Inc.

    CERT - Senseonics Holdings, Inc. (0001616543) (Filer)

    11/14/25 12:32:49 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    SEC Form 8-A12B filed by Senseonics Holdings Inc.

    8-A12B - Senseonics Holdings, Inc. (0001616543) (Filer)

    11/14/25 7:01:18 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Director Steven Edelman bought $65,500 worth of shares (10,000 units at $6.55), increasing direct ownership by 15% to 74,708 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    11/13/25 4:48:53 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Sullivan Frederick T. bought $31,840 worth of shares (5,415 units at $5.88), increasing direct ownership by 4% to 157,028 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    11/10/25 7:40:12 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Director Roeder Douglas A bought $87,450 worth of shares (15,000 units at $5.83), increasing direct ownership by 18% to 99,727 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    11/10/25 7:40:13 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $SENS
    Leadership Updates

    Live Leadership Updates

    View All

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $SENS
    Financials

    Live finance-specific insights

    View All

    Senseonics Holdings, Inc. Reports Third Quarter Financial Results

    Generated Q3 revenue of $8.1 million, representing year-over-year growth of 90% Achieved a 160% increase in U.S. new patient starts over prior year Planning for the transition of CGM commercial responsibility from Ascensia Diabetes Care back to Senseonics GERMANTOWN, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the third quarter ended September 30, 2025. Recent Highlights & Accomplishments: Generated revenue of $8.1 million in the third quarter of 2

    11/5/25 4:05:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Holdings, Inc. Schedules Third Quarter 2025 Earnings Release and Conference Call for November 5, 2025 at 4:30 P.M. Eastern Time

    GERMANTOWN, Md., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2025 financial results after market close on Wednesday, November 5, 2025. Management will hold a conference call to review the Company's third quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by na

    10/22/25 4:05:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365

    CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics Brian Hansen to be appointed Chief Commercial Officer Non-dilutive debt facility expanded up to $100 million with Hercules Capital to fund commercial organization Conference Call scheduled for September 4, 2025 at 8:00 A.M. Eastern Time GERMANTOWN, Md., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced a mutually executed Memorandum of Understanding to transition all commercialization and distributio

    9/3/25 5:17:09 PM ET
    $HTGC
    $SENS
    Investment Managers
    Finance
    Medical/Dental Instruments
    Health Care

    $SENS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Senseonics Holdings Inc. (Amendment)

    SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)

    2/13/24 5:13:59 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Senseonics Holdings Inc. (Amendment)

    SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)

    7/7/23 4:35:55 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Senseonics Holdings Inc.

    SC 13G - Senseonics Holdings, Inc. (0001616543) (Subject)

    4/10/23 5:10:45 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care